Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -61.54%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced a loss of $0.20, delivering a surprise of -433.33%.Over the last four quarters, the compa ...

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund Operations I ...

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Thursday, November ...

Adherex Technologies Inc. (FENC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they mi ...

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host oneon-one investor meetings at the conferences. Conference Details: Event: H.C. Wainwright Global Investment Conference Date: September 11, 2024 Time: Company Presentation at 12:00 p.m. – 12:30 p.m. ET Location: New Y ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____ to ____ Commission File Number: 001-32295 FENNEC PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig Hallum Naureen Quibria - Capital One Securities Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Second Quarter 2024 Earnings and Corporate Update Conference Call. [Operator Instructions] As a reminder ...

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -433.33%. A quarter ago, it was expected that this company would post earnings of $0.49 per share when it actually produced earnings of $0.41, delivering a surprise of -16.33%. Over the last four quarters, the company has ...

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial res ...

RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024 financial results and provide a business update before the opening of the U.S. financial markets on Tuesday, August 13, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast De ...